RFK Jr.'s made promises about vaccines. Here's what he's done as health secretary
During his Senate confirmation hearings, Health Secretary Robert F. Kennedy Jr. suggested he wouldn't undermine vaccines.
'I am not going to go into HHS and impose my preordained opinions on anybody at HHS,' he said. 'I'm going to empower the scientists at HHS to do their job and make sure that we have good science that is evidence based.'
He also said he wouldn't halt congressionally mandated funding for vaccination programs, nor impose conditions that would force local, state or global entities to limit access to vaccines or vaccine promotion.
'I'm not going to substitute my judgment for science,' he said.
Yet the Department of Health and Human Services under Kennedy has taken unprecedented steps to change how vaccines are evaluated, approved and recommended — sometimes in ways that run counter to established scientific consensus.
Here's a look at what Kennedy has said and done since becoming the nation's top health official on Feb. 13.
Kennedy and the childhood vaccine schedule
Sen. Bill Cassidy, a physician who was unsettled about Kennedy's antivaccine work, said Kennedy pledged to him that he wouldn't change existing vaccine recommendations.
'I recommend that children follow the CDC schedule. And I will support the CDC schedule when I get in there,' Kennedy said at his Senate confirmation hearing.
Kennedy also said he thought the polio vaccine was safe and effective and that he wouldn't seek to reduce its availability.
Feb. 18: Kennedy vows to investigate the childhood vaccine schedule that prevents measles, polio and other dangerous diseases.
Early March: The National Institutes of Health cancels studies about ways to improve vaccine trust and access.
April 9: Kennedy tells CBS News that 'people should get the measles vaccine, but the government should not be mandating those,' before then continuing to raise safety concerns about vaccines.
May 22: Kennedy issues a report that, among other things, questioned the necessity of mandates that require children to get vaccinated for school admission and suggested that vaccines should undergo more clinical trials, including with placebos. The report has to be reissued later because the initial version cited studies that don't exist.
May 30: The Centers for Disease Control and Prevention removes COVID-19 vaccination guidance for pregnant women and says healthy children 'may' get the shots.
June 25: A group of vaccine advisers picked by Kennedy announce they are establishing a work group to evaluate the 'cumulative effect' of the children's vaccine schedule.
June 25: Kennedy announces the U.S. will stop supporting the vaccines alliance Gavi. He accuses the group, along with the World Health Organization, of silencing 'dissenting views' and 'legitimate questions' about vaccine safety.
Kennedy on revising CDC vaccine recommendations
At the confirmation hearing, Cassidy asked Kennedy: 'Do you commit that you will revise any CDC recommendations only based on peer review, consensus based, widely accepted science?'
Kennedy replied, 'Absolutely,' adding he would rely on evidence-based science.
Feb. 20: HHS postpones a meeting of outside vaccine advisers.
April 16: The CDC's vaccine advisory panel meets and recommends that people 50 to 59 with certain risk factors should be able to get vaccinated against respiratory syncytial virus, and endorses a new shot that protects against meningococcal bacteria. As of late June, the CDC and HHS haven't acted on the recommendations.
May 27: Kennedy announces that COVID-19 vaccines are no longer recommended for healthy children and pregnant women — a move immediately questioned by several public health experts. No one from the CDC, the agency that makes such recommendations, is present in the video announcing the changes.
June 9: Kennedy ousts all 17 members of the science panel that advises the CDC on how vaccines should be used.
June 11: Kennedy names new vaccine policy advisers to replace the panel that he dismissed. They include a scientist who rose to prominence by relaying conspiracy theories around the COVID-19 pandemic and the vaccines that followed, a leading critic of pandemic-era lockdowns, a business school professor, and a nurse affiliated with a group that is widely considered to be a leading source of vaccine misinformation.
June 26: Kennedy's vaccine advisers recommend that people receive flu shots free of an ingredient that antivaccine groups have falsely tied to autism. The vote comes after a presentation from an antivaccine group's former leader. A CDC staff analysis of past research on the topic is removed from the agency's website because, according to a committee member, the report hadn't been authorized by Kennedy's office.
Kennedy on vaccine approvals and review standards
At the Senate hearing, Cassidy asked Kennedy if he would keep FDA's historically rigorous vaccine review standards.
'Yes,' Kennedy replied.
March 29: Kennedy forces the FDA's top vaccine official to resign. The official, Peter Marks, says he feared Kennedy's team might manipulate or delete data from a vaccine safety database.
May 6: Kennedy names Dr. Vinay Prasad, an outspoken critic of the FDA's handling of COVID-19 boosters, as the FDA's vaccine chief.
May 16: After a delay, the FDA grants Novavax full approval for its COVID-19 vaccine but with unusual restrictions: The agency says it's for use only in adults 65 and older – or those 12 to 64 who have at least one health problem that puts them at increased risk from COVID-19.
May 20: Top officials limit the approval for seasonal COVID-19 shots to seniors and others at high risk, pending more data on everyone else. The FDA urges companies to conduct large, lengthy studies before tweaked vaccines can be approved for healthier people, a stark break from the previous federal policy recommending an annual COVID-19 shot for all Americans six months and older.
May 30: FDA approves a new COVID-19 vaccine made by Moderna but with the same limits on who can get it as Novavax's shot.
Kennedy on bird flu vaccine
At his confirmation hearing, Kennedy said he would support the development of a vaccine for H5N1 bird flu.
'I'm going to continue research on every kind of vaccine,' he said.
May 28: The Biomedical Advanced Research and Development Authority, an HHS agency, cancels $766 million in awards to Moderna to develop a vaccine against potential pandemic influenza viruses, including the H5N1 bird flu.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
As new variant spreads, what's the latest COVID-19 vaccine guidance? It's complicated.
As a new COVID-19 variant takes over in the U.S., guidance surrounding vaccines has become increasingly confusing. Changes in vaccination guidelines, ever-evolving variants and strains, along with threats to health insurance, have sent average Americans looking for the latest recommendations as members of the federal government often conflict with independent medical agencies and healthcare professionals. In the two weeks leading up to June 21, the Centers for Disease Control and Prevention (CDC) reported just shy of 14,500 positive COVID tests, and while hospitalizations and deaths are fortunately down significantly since the pandemic's peak, vulnerable people are still grappling with limiting their risk amid changing practices. Having trouble keeping track of variants and vaccines? Here's what we know. NB.1.8.1 is one of the latest variants of COVID-19, a "slightly upgraded version" of the LP.8.1 variant that is prominent right now, Subhash Verma, microbiology and immunology professor at the University of Nevada, Reno, previously told USA TODAY in May. Verma previously stated that NB.1.8.1 may be transferred more easily than LP.8.1. Additionally, he noted that NB.1.8.1 can evade antibodies created by vaccines or past infections more easily than LP.8.1. In early April, NB.1.8.1 accounted for 0% of COVID cases in the U.S. In the two weeks ending June 21, it accounted for the majority of cases at 43%, according to the CDC. The variant has similar symptoms to other strains, including fever or chills, cough, shortness of breath or difficulty breathing, sore throat, congestion or a runny nose, new loss of taste or smell, fatigue, muscle or body aches, headache, nausea or vomiting. One of its more unique features is "razor blade throat," reported by patients as an exceptionally sore throat. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. said on May 27 that the COVID-19 vaccine would no longer be included in the CDC's recommended immunization schedule for healthy children and pregnant women, a move that broke with previous expert guidance and bypassed the normal scientific review process. Under the changes, the only people who will be recommended for COVID-19 vaccines are those over 65 and people with existing health problems. This could make it harder for others who want the COVID-19 vaccine to get it, including health care workers and healthy people under 65 with a vulnerable family member or those who want to reduce their short-term risk of infection. The American College of Obstetricians and Gynecologists (ACOG) and American Academy of Pediatrics (AAP), among other organizations, issued statements condemning the change, with the ACOG saying it was "...concerned about and extremely disappointed by the announcement that HHS will no longer recommend COVID-19 vaccination during pregnancy." "It is very clear that COVID-19 infection during pregnancy can be catastrophic and lead to major disability, and it can cause devastating consequences for families. The COVID-19 vaccine is safe during pregnancy, and vaccination can protect our patients and their infants after birth," President Steven J. Fleischman said in a statement. Insurance coverage typically follows federal recommendations, so anyone who is healthy and under 65 is likely to have to pay out of pocket to get the shot, which runs about $200, if they can get it. It's not clear what insurance companies will do about the new recommendations. The American Medical Association (AMA) and American Academy of Pediatrics (AAP), in partnership with other professional medical organizations, broke from RFK and HHS after this announcement, sharing plans to develop their own guidelines independent of the government organization. In an open letter signed by 80 medical organizations across the country and published on June 25, the AMA called for physicians, healthcare networks and insurance companies to continue supporting "evidence-based immunizations to help prevent severe disease and protect public health." "Vaccines for influenza, RSV, and COVID-19 remain among the best tools to protect the public against these illnesses and their potentially serious complications—and physicians are among the most trusted voices to recommend them. We come together as physicians from every corner of medicine to reaffirm our commitment to these lifesaving vaccines," the letter said. "Recent changes to federal immunization review processes raised concerns across the medical and public health community. In this moment of uncertainty, physicians must align around clear, evidence-based guidance for patients." The AAP likewise said in a June 26 statement that it will "continue to publish its own evidence-based recommendations and schedules." AAP President Susan J. Kressly said the creation of federal immunization policy is 'no longer a credible process," adding, "...we're not stepping back, we're stepping up. The AAP will continue to publish our own immunization schedule just as we always have, developed by experts, guided by science, trusted by pediatricians and families across the country.' These latest independent guidelines have yet to be released. Meanwhile, the new Advisory Committee on Immunization Practices (ACIP) gathered for the first time on June 25 in a meeting that drew criticism from some experts. RFK fired all 17 original members of the committee on June 9, replacing them with members that critics have called unqualified. Some of the members, like Kennedy, have a history of anti-vaccine advocacy, prompting backlash that had doctors and organizations calling for a delay in the meeting. Anti-vaccine sentiments were repeated by ACIP Chair Martin Kulldorf at the meeting, who said the panel will be "investigating" MMR and childhood vaccines. The CDC panel also reviewed data about COVID-19 vaccines, questioning their safety and effectiveness. They also raised questions about the study design, methodologies and surveillance monitoring systems behind the data, which Dr. Pamela Rockwell, clinical professor of family medicine at the University of Michigan Medical School, addressed as a standard of medical research. "Our efforts, through a very robust system of checks and balances, are to create vaccines and vaccination programs that result in the most benefit with the least harm," said Dr. Gretchen LaSalle, a family physician in Spokane, Washington, who represented the American Academy of Family Physicians. Despite this, the committee didn't vote on COVID-19 vaccine recommendations for the fall and isn't expected to reconvene until 'September/October,' according to the CDC website. ACIP commitee: Inside the unusual, RFK-appointed panel that's deciding on childhood vaccines The FDA likewise announced updated requirements for mRNA COVID-19 vaccine warning labels on June 25, which apply to Comirnaty by Pfizer Inc. and Spikevax by ModernaTX Inc. Prescribing information will now include warnings of the connection between the vaccines and a rare side effect that causes inflammation of the heart muscle and lining. The new warning label discloses the risk of myocarditis, which appeared in 8 cases per 1 million people who got the 2023-2024 COVID shots between the ages of 6 months and 64 years old, mostly commonly among males aged 12 to 24. The previous label, which also disclosed the risk, said the problem mostly occurred in minors aged 12-17. Despite the back-and-forth in the U.S., the World Health Organization (WHO) has kept its recommendation consistent. Currently approved COVID-19 vaccines are expected to remain effective against the NB.1.8.1 variant, it said. In a webpage dated Jan. 7, the CDC advised that everyone over the age of six months get the 2024-2025 COVID-19 vaccine, specifically the 2024-2025 Moderna COVID-19 Vaccine. The page has since been updated with a banner, reading "COVID-19 vaccine recommendations have recently been updated for some populations. This page will be updated to align with the updated immunization schedule." The original recommendations align with the WHO's current guidelines. WHO, AMA, AAP and existing standards recommend that people who have never received a COVID-19 vaccine, are age 65 and older, are immunocompromised, live at a long-term care facility, are pregnant, breastfeeding, trying to get pregnant, and/or want to avoid getting long COVID, should get the vaccine, especially. Contributing: Greta Cross, Adrianna Rodriguez, USA TODAY This article originally appeared on USA TODAY: What are the latest COVID vaccine guidelines for this summer?


Associated Press
14 minutes ago
- Associated Press
RetinalGenix Technologies Contracts with LabCorp to Support DNA/GPS Platform for Advanced Genetic and Retinal Health Screening
APOLLO BEACH, Fla., June 27, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. OTCQB:RTGN ('RetinalGenix' or the 'Company'), a pioneering developmental-stage company focused on ophthalmic screening, monitoring, pharmacogenetic mapping, and repurposed drug development for early detection and treatment of eye and systemic diseases, has entered into an agreement with LabCorp, one of the nation's largest laboratory services organizations, to support the rollout of the RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform. This innovative program enables patients to undergo genetic testing and high-resolution retinal imaging anonymously and provide insights into both ocular and systemic diseases. Through this collaboration, patients may visit any USA-based LabCorp location to have blood, tears, nasal secretions, and saliva collected and analyzed using proprietary algorithms developed by the RetinalGenix and DNA/RNA GPS analysis platform. These tests may correlate genetic and retinal biomarkers seeking to establish a new standard for early detection of a wide range of health conditions. Based on tests recommended by RetinalGenix, patients may elect to have their data analyzed using specific algorithms developed by RetinalGenix. This process is paired with DNA/RNA/GPS to correlate with current and future biomarkers found in the eye and the blood. Dr. Larry Perich, DO, Advisor for the DNA/RNA/GPS program, noted, 'As the database of disease-associated biomarkers expands, we expect the value of these platforms for diagnosing both ocular and systemic diseases continues to grow, promising improved outcomes and more accessible care.' Patients maintain full control of their health records, which remain anonymous and confidential. Appointments and test orders are managed via the RetinalGenix online platform, with results securely released to patients upon validation of payment at their chosen LabCorp center. Dr. Taimour Langaee, PhD, oversees the Company's DNA/GPS genotyping/sequencing data processing, genetic and pharmacogenomics data analyses, and clinical genetic association studies between eye diseases and genetic variations. Dr. Langaee said, 'I am excited that this creates great opportunities to further expand our knowledge about the important role of genetics and precision medicine in eye diseases, affecting millions of people and the potential to discover novel genetic variants and treatments.' High-resolution retinal imaging will be introduced by RetinalGenix as a value-added additional service at various locations in the near future. The integration of high-resolution imaging is expected to further boost diagnostic accuracy, allowing even general practitioners and standard eye clinics to assist in patient mass screening. These innovations are designed to make screening more accessible, cost-effective, and capable of detecting disease at earlier, more treatable stages. 'The cost of healthcare is enormous, and patient access is critical. This cost-effective methodology aims to reduce reliance on expensive diagnostic procedures such as MRIs, CT scans, PET Scans, echocardiograms to name a few, helping to alleviate the financial burden on both patients and the healthcare system. Equally important is avoiding the use of high-priced specialists to perform basic eye care services. The company is actively collaborating with regulators to establish CPT codes, which should lower healthcare costs and improve access to necessary evaluations. By doing so, the already overburdened patient assessment process can be streamlined,' stated Jerry Katzman, MD, RetinalGenix Technologies CEO. About RetinalGenix RetinalGenix is an ophthalmic research and development company seeking to revolutionize early disease detection and improve patient outcomes across multiple disease areas by integrating genetic screening, advanced imaging, and therapeutic development. Its proprietary High-Resolution Retinal Imaging and RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular, and metabolic systems, as well as diabetic conditions, Alzheimer's disease and Parkinson's disease. RetinalGenix is also developing therapeutic drugs for dry age-related macular degeneration (dry AMD) and Alzheimer's disease/dementia. Safe Harbor Statement This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words 'could,' 'believe,' 'anticipate,' 'intend,' 'estimate,' 'expect,' 'may,' 'continue,' 'predict,' 'potential,' 'project' and similar expressions that are intended to identify forward-looking statements and include statements regarding reducing reliance on expensive diagnostic procedures with the Company's methodology, the planned rollout of the RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform, the program providing insights into both ocular and systemic diseases, correlating genetic and retinal biomarkers to seek to establish a new standard for the early detection of a wide range of health conditions, the value of platforms for diagnosing both ocular and systemic diseases continuing to grow, promising improved outcomes and more accessible care, the opportunities to further expand our knowledge about the important role of genetics and precision medicine in eye diseases and the potential to discover novel genetic variants and treatments, introducing high-resolution retinal imaging as an additional service in the near future, the integration of high-resolution imaging further boosting diagnostic accuracy, allowing even general practitioners and standard eye clinics to assist in patient mass screening, the innovations making screening more accessible, cost-effective, and capable of detecting disease at earlier, more treatable stages, establishing CPT codes to further lower healthcare costs and improve access to necessary evaluations and streamlining the patient assessment process. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company's ability to successfully complete research and further development and commercialization of Company products, the timing, cost and uncertainty of obtaining regulatory approvals for the Company's products, the Company's ability to protect its intellectual property, and the risk factors described in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and the Company's subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law. Media Contact: For further information, please contact: RetinalGenix Technologies Inc. Media and Investor Relations [email protected] (800) 331-5446

Yahoo
26 minutes ago
- Yahoo
Report finds five north country hospitals at risk if Republican Medicaid cuts pass Congress
Jun. 26—Five hospitals in the north country could be faced with steep cuts to their operating revenues if the budget bill Republicans are pushing through Congress right now passes, according to analysis from the University of North Carolina, Chapel Hill's Sheps Center for Health Services Research. Analysis from the center found that rural hospitals across the country would be majorly hurt by the Medicaid cuts the Republican budget bill calls for, because rural hospitals often have a significant portion of their patient pool, sometimes a majority of it, in the Medicaid or Medicare programs that serve poor and elderly people, respectively. The Sheps Center looked for hospitals that are both in the top 10% of Medicaid payer mix, meaning they have the largest proportions of Medicaid patients to non-Medicaid patients, and that have reported three straight years of negative total operating margins, meaning they've been paying out more money than they've been taking in. In New York, 11 hospitals fit that criteria, including 5 in the north country; Claxton-Hepburn Medical Center in Ogdensburg, Massena Hospital, Clifton-Fine Hospital in Star Lake, Gouverneur Hospital and Lewis County General Hospital in Lowville. Ogdensburg and Lowville are not considered top Medicaid providers, but they do each serve a significant number of Medicaid recipients each year and both demonstrate negative annual margins. The Sheps Center analysis posits that the cuts to Medicaid, which come from a combination of changes to federal support for Medicaid spending, expanded work requirements and adjustments to the fees and taxes states can charge providers, would result in significant numbers of everyday Americans being kicked off of the program. Those people would still need emergency medical care as they receive at hospitals, which have a duty to provide it, but those hospitals would no longer be paid for the care they provide at all. In a letter to President Donald J. Trump and the Republican leaders in the House and Senate, Sen. Charles E. Schumer, D-N.Y., and three other Democratic Senate leaders implored them to reverse course on the Medicaid cuts outlined in the reconciliation bill, which Trump has named the "One Big Beautiful Bill." "Many of these rural hospitals are facing financial instability today, even before any of the Republican health care cuts take effect," their letter reads. "Rural hospitals will be disproportionately impacted by health care cuts. Addressing the crisis in rural health care access is a national, bipartisan priority, and it should be bipartisan to not worsen it. However, if your party passes these health care cuts into law, Americans in rural communities across the country risk losing health care services and jobs supported by their local hospitals." State Democrats are criticizing north country Rep. Elise M. Stefanik, R-Schuylerville, for backing the bill and continuing to support it as Republicans push it to final approval. "Five hospitals in Elise Stefanik's district are on the chopping block because of her vote for the largest cut to Medicaid in history," said Addison Dick, spokesperson for the state Democratic Party. "Instead of fighting for her constituents, Stefanik is caving to Trump and supporting his budget that will rip away coverage, increase health care costs, and devastate rural health care." A spokesperson for Stefanik pushed back on the claims that the Medicaid provisions in the reconciliation package will result in loss of coverage for her constituents, which he called an "indespensible lifeline for our nation's most vulnerable." "However, far left Democrats continue to fearmonger because they know that President Trump is delivering results for the American people," the spokesperson said. "He ran on the promise that he would root out the wasteful and fraudulent government spending. In New York alone, an estimated $20 billion is spent on fraudulent Medicaid claims annually. On top of this insurmountable burden resting on the shoulders of hardworking taxpayers, illegals are also eligible for Emergency Medicaid which has ballooned more than 1,200 percent since 2014. This spending is unsustainable and in order to continue protecting and preserving benefits for America's most vulnerable, waste, fraud, and abuse must be rooted out." The Empire Center for Public Policy, a conservative New York think tank, found in late 2024 that as many as 3 million New Yorkers may be fraudulently collecting Medicaid and other health insurance benefits from the state, basing their analysis off of census data and information obtained from the state Medicaid program. Overall, 44% of New Yorkers receive Medicaid or a similar program, including children on the state-level Child Health Plus program and the New York Essential Plan, provided through the American Care Act health insurance marketplace and providing Medicaid-like coverage to people making up to 250% of the federal poverty level. The Empire Center also found earlier this year that the state program to offer emergency medicaid to undocumented immigrants, which has 480,000 people enrolled as of March, represents 7% of total Medicaid enrollment in the state. If the reconciliation package passes into law with the provisions for Medicaid included in the House-passed version, the federal government could cut the money it pays to the state for its portion of Medicaid funding, which would reduce available benefits for all recipients. Stefanik, who has floated a run for governor next year and has made criticisms of state programs aiding undocumented immigrants a core part of her early, pre-campaign message, said in a visit to Albany last month that she would seek to use executive actions and push the state legislature to end the emergency Medicaid program and cut down on fraud if elected. Gov. Kathleen C. Hochul, who is running for reelection, has not expressed any interest in changing that aspect of the state's Medicaid operations. It's not clear if the final package will include the major Medicaid provisions as passed by the House. On Thursday, the U.S. Senate Parliamentarian, which is charged with ensuring all actions taken by that chamber follow the proper laws and procedures, struck many of the most impactful Medicaid provisions from the bill for procedural reasons. Whatever resulting legislation passes in the U.S. Senate will have to go back to the House for a final vote before it can go to the president for approval. The two chambers have not seen eye to eye on many aspects of the reconciliation bill. Trump has demanded that lawmakers deliver a finished bill to his desk by July 4.